Leoni Mollie sold 28,802 shares of Kura Oncology, Inc. at $10.75 for −$310k on Sep 29, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Medical Officer
Chief Medical Officer
Filed Sep 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$309,566.78Shares × reported price
Shares traded
28,802Common Stock
Price per share
$10.75Reported price. Read footnotes for ranges.
% of reported position traded
16.95%This security and ownership context
Holdings after
141,095Direct
Trade date
Sep 29, 2026Sell
Filed
Sep 29, 2026, 6:30 PM ET0-day reporting delay
Accession
0001193125-26-407937Code S · Transaction 231314
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 169,897 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 28, 2026Sell12,448$10.50−$130,670.39Trade 231313
2 transaction rows in this filing. Joint filers share the same rows.

KURA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KURA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +17%1w ago +8.6%1d ago −1.8%
Returns since7d −2.5%30d −2.2%90d180d1y

Footnotes in full

F1: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The one-year anniversary of the specified development milestone was determined to be met on September 27, 2026, resulting in the vesting of 1/6th of the underlying shares. F2: The shares sold were acquired by the Reporting Person upon vesting of performance restricted stock units on September 27, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2026. F3: This transaction was executed in multiple trades at prices ranging from $10.53 to $10.89. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.